Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry

Clement Delmas1*, François Roubille2, Nicolas Lamblin3, Laurent Bonello4, Guillaume Leurent5, Bruno Levy6, Meyer Elbaz1, Nicolas Danchin7, Sebastien Champion8, Pascal Lim9, Francis Schneider10, Alain Cariou11, Hadi Khachab12, Jeremy Bourenne13, Marie-France Seronde14, Guillaume Schurtz9, Brahim Harbaoui15, Gerald Vanzetto16, Charlotte Quentin17, Xavier Delabranche18, Nadia Aissaoui19, Nicolas Combaret20, Stephane Manzo-Silberman21, Danka Tomasevic22, Benjamin Marchandot23, Benoit Lattuca24, Patrick Henry21, Edouard Gerbaud25, Eric Bonnefoy22 and Etienne Puymirat7

Aims Published data on cardiogenic shock (CS) are scarce and are mostly focused on small registries of selected populations. The aim of this study was to examine the current CS picture and define the independent correlates of 30 day mortality in a large non-selected cohort.

Methods and results FRENSHOCK is a prospective multicentre observational survey conducted in metropolitan French intensive care units and intensive cardiac care units between April and October 2016. There were 772 patients enrolled (mean age 65.7 ± 14.9 years; 71.5% male). Of these patients, 280 (36.3%) had ischaemic CS. Organ replacement therapies (respiratory support, circulatory support or renal replacement therapy) were used in 58.3% of patients. Mortality at 30 days was 26.0% in the overall population (16.7% to 48.0% depending on the main cause and first place of admission). Multivariable analysis showed that six independent factors were associated with a higher 30 day mortality: age [per year, odds ratio (OR) 1.06, 95% confidence interval (CI): 1.04–1.08], diuretics (OR 1.74, 95% CI: 1.05–2.88), circulatory support (OR 1.92, 95% CI: 1.12–3.29), left ventricular ejection fraction <30% (OR 2.15, 95% CI: 1.40–3.29), norepinephrine (OR 2.55, 95% CI: 1.69–3.84), and renal replacement therapy (OR 2.72, 95% CI: 1.65–4.49).

Conclusions Non-ischaemic CS accounted for more than 60% of all cases of CS. CS is still associated with significant but variable short-term mortality according to the cause and first place of admission, despite frequent use of haemodynamic support, and organ replacement therapies.

Keywords Cardiogenic shock; Epidemiology; Mortality; Organ support

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Cardiogenic shock (CS) is a syndrome caused by a primary cardiovascular disorder in which inadequate cardiac output results in life-threatening tissue hypoperfusion associated with tissue oxygen metabolism impairment and hyperlactatemia, which, depending on the severity, can result in multi-organ dysfunction and death. While in clinical practice there is a spectrum of presentations, clinical trials have used specific haemodynamic parameters to define CS. The common definition of CS in the SHOCK trial requires the presence of three major haemodynamic parameters: (i) persistent hypotension defined as systolic blood pressure (SBP) < 90 mmHg (or mean arterial pressure 30 mmHg below the baseline), (ii) decreased cardiac index (< 1.8 L/min/m² without support or < 2.2 L/min/m² with support) with, (c) adequate or elevated filling pressure (left ventricular end-diastolic pressure > 18 mmHg or right ventricular end-diastolic pressure > 10 to 15 mmHg). These haemodynamic parameters, while necessary when enrolling patients in clinical trials, may not be universally applicable in clinical practice.

Inclusion criteria used to define CS in a study are not the only parameters of a study population to be considered. The study setting for prehospital, intensive cardiac care unit (ICCU) or general intensive care unit (ICU) provides patients with different characteristics and severity; hence the interest of studies on CS that recruit patients from different settings.

Ischaemic CS that complicates approximately 3–9% of the cases of acute myocardial infarction (AMI) was reported to be the most common cause of CS3–7 and confers a severe prognosis associated with a high hospital mortality rate of 24.6–51.0%. Data regarding non-ischaemic CS are limited probably in part because all the definitions of CS used are based only on AMI CS and the major studies have focused on ischaemic CS to evaluate management (myocardial revascularization, circulatory support and medications).2,3 However, patients with non-ischaemic CS could represent more than 50% of all the cases of CS and may be associated with a better prognosis.10–14

The aim of this analysis is to report the baseline characteristics, management and independent correlates of 30-day mortality in patients with CS in routine clinical practice included in the FRENSHOCK multicentre registry, regardless of the aetiology and the initial place of admission.

Methods

Patient population

FRENSHOCK is a prospective multicentre observational study conducted in metropolitan France during a 6 month period between April and October 2016 in ICU and ICCU (NCT02703038). The methods used for this registry have been previously described. Briefly, the primary objective was to evaluate the characteristics, management, and outcomes of CS patients, with a new modified definition of CS. Supporting information, Table S1 as seen in routine clinical practice, on a nation-wide scale.

All adult patients (≥18 years old) with CS were prospectively included in this registry if they met at least one criterion of each of the following three components: (i) haemodynamic criteria, defined as a low SBP < 90 mmHg and/or the need for maintenance with vasopressors/inotropes and/or a low cardiac index < 2.2 L/min/m², (ii) left and/or right heart pressure elevation, defined by clinical signs, radiology, blood tests, echocardiography, or signs of invasive haemodynamic overload; and (iii) signs of organ malperfusion, which could be clinical and/or biological. Patients admitted after cardiopulmonary resuscitation were included if they fulfilled previously defined CS criteria. Patients could be included regardless of CS aetiology, and whether CS was primary or secondary. Exclusion criteria were refusal or the inability to consent and a diagnosis of CS refuted in favour of alternative diagnoses, such as septic shock, refractory cardiac arrest and post-cardiotomy CS.

All institutions were invited to participate in the study, including university teaching hospitals, general and regional hospitals, public and private hospitals that manage CS patients (ICCs, surgical ICUs, medical ICUs and general ICUs). The study was conducted in accordance with the guidelines for good clinical practice and French law. Written consent was obtained for all the patients. The data recorded and their handling and storage were reviewed and approved by the CCTIRS (French Health Research Data Processing Advisory Committee) (n° 15.897) and the CNIL (French Data Protection Agency) (n° DR-2016-109).

Data collection

Data on baseline characteristics, including demographics (age, gender, body mass index, social status), risk factors
with a threshold cause mortality, binary logistic regression analyses were used, included in the variance for continuous variables and are described in numbers and percentages. Groups (30 day and interquartile ranges when appropriate. Discrete variables continuous variables are reported as means (SD) or medians infectious disease; non-compliance (poor compliance with medical treatment or hygiene and diet rules, for example, stopping or skipping an angiotensin-converting enzyme inhibitor or beta blocker treatment, deviation from a low sodium diet, etc.); or iatrogenesis. Investigators could also note other existing factors or aetiologies. Such triggering factors were indicated as ‘other’. Information regarding the use of cardiac procedures, that is, coronary angiography and/or percutaneous coronary intervention (PCI); right heart catheterization; the need for medications (inotropes, vasopressors, diuretics, and fibrinolysis) and organ replacement therapies such as mechanical ventilation (invasive or non-invasive); temporary mechanical circulatory support [intra-aortic balloon pump (IABP); extracorporeal membrane oxygenation or Impella® (Abiomed, Danvers, MA, USA)]; and renal replacement therapy (continuous or intermittent) were collected.

In-hospital complications, such as stroke, bleeding and transfusions, haemolysis, thrombocytopenia, nosocomial infections, vascular complications, and death, were noted. Information on mortality was obtained directly by the local investigators (cause and date).

Results

Study population

A total of 772 CS patients were included in 49 centres. Clinical characteristics are presented in Table 1. CS criteria used to define CS are reported in Table S2. The main criteria were hypotension and/or echocardiographic parameters for the haemodynamic criteria, clinical parameters for the overload criteria, and biological parameters for the organ malperfusion criteria. Less than 8% of the patients were diagnosed based on invasive parameters of CS. Mean age of the population was 65.7 (±14.9) years with a predominance of men (71.5%). The rate of hypertension, dyslipidaemia, diabetes mellitus, and current smoking were high, respectively, 47.2%, 35.9%, 28.1%, and 26.7%. A history of cardiac disease was reported in 56.1% (29.8% coronary artery disease), previous PCI in 21.5%, previous stroke in 8.0%, PAD in 11.8%, and CKD in 21.2%.

At admission, mean SBP was 101 (±25) mmHg and mean heart rate was 96 (±30) bpm (Table 2). Clinical signs of left and right heart failure were frequent with 72.5% and 50% respectively. Mottling was reported in 37.5% of the cases. The main triggers of CS (not mutually exclusive) were ischaemic (36.3%), supra ventricular arrhythmias (13.3%), ventricular arrhythmias (12.6%), and infectious disease (11.9%) (Figure 1). Cardiac arrest occurred in 10.3% of patients. Most patients had multiple organ failure as evidenced by kidney dysfunction, hepatic cytolysis and cholestasis, and lactate elevation.

Seven hundred and sixty patients (98.5%) had an echocardiography at admission. Left ventricular ejection fraction (LVEF) <40% was reported in 80.7% of the patients and <30% in 61.4%.

Vitals parameters at 24 h after admission are detailed in Table S3.

In-hospital management

In-hospital management is reported in Table 3. Most patients were directly admitted in ICCU (56.1%); 23.1% were admitted
in ICU, and 13.3% were transferred from another centre (emergency or another department).

Intravenous diuretics were used in 82% of the cases. Dobutamine was the most used inotrope (81.9%) at low to intermediate doses (5–10 μg/kg/min). Norepinephrine was used in 53.1% of the patients, a dobutamine—norepinephrine combination in 45.6%, and epinephrine in 12.4%. Use of levosimendan (7.4%), dopamine (0.3%), milrinone (1.8%), and enoximone (0.4%) was minimal. Use of invasive and non-invasive ventilation was 37.9% and 25.9%, respectively. Circulatory support was provided in 18.6% of the cases. Extracorporeal life support was the most frequent type of assistance (85/143, 59.4%). Finally, renal replacement therapy was provided in 15.8% of the cases. Overall, 41.7% had no organ support (no respiratory, or circulatory support, and no renal replacement therapy).

Coronary angiography was performed in 399 patients (51.7%), 63.7% of whom had significant coronary disease (one-vessel, two-vessel, and three-vessel disease in 20.1%, 22.8%, and 21.8%, respectively). A PCI was performed for 54.4% of those who had a coronary angiogram.

### Thirty-day outcome and correlates

In-hospital complications are listed in Table S4. Pneumonia was the most frequent infection reported (19.7%) and the rate of severe bleeding was 12.4% (mainly digestive bleeding) (Figure 2).

At Day 30, two patients were lost to follow-up (0.26%). Mortality rate at 30 days was 26.0% in the overall population and differed according to initial place of admission [22.2% for overall population, 15.2% in those transferred from another centre (emergency or another department), and 27.3% in those admitted to ICU].

#### Table 1 Clinical characteristics at admission according to vital status at 30 days

| Overall population (n = 772) | 30 day survivors (n = 571) | 30 day non-survivors (n = 201) | P value |
|-----------------------------|---------------------------|-------------------------------|--------|
| Age, mean ± SD, years       | 65.7 ± 14.9               | 64.0 ± 14.8                   | 70.4 ± 14.3 | <0.001 |
| Male, n (%)                 | 552 (71.5)                | 407 (71.3)                    | 145 (72.1) | 0.82   |
| Body mass index, mean ± SD, kg/m² | 25.8 ± 5.6               | 25.9 ± 5.5                    | 25.6 ± 5.9 | 0.47   |
| Employment status, n (%)    |                           |                               |         |
| Employed                    | 128 (16.6)                | 108 (18.9)                    | 20 (10)  | <0.001 |
| Unemployed                  | 25 (3.1)                  | 21 (3.7)                      | 4 (2.0)  |        |
| Househusband/wife           | 14 (1.8)                  | 12 (2.1)                      | 2 (1.0)  |        |
| Disability                  | 56 (7.3)                  | 35 (6.1)                      | 21 (10.4) |        |
| Retired                     | 448 (58.0)                | 308 (53.9)                    | 140 (69.7) |        |
| Risk factors, n (%)         |                           |                               |         |
| Current smoker              | 206 (26.7)                | 159 (27.8)                    | 47 (23.4) | 0.22   |
| Diabetes mellitus           | 217 (28.1)                | 166 (29.1)                    | 51 (25.4) | 0.41   |
| Hypertension                | 364 (47.2)                | 263 (46.1)                    | 101 (50.2) | 0.51   |
| Dyslipidaemia               | 277 (35.9)                | 205 (35.9)                    | 72 (35.8) | 0.84   |
| Medical history, n (%)      |                           |                               |         |
| History of cardiac disease  | 433 (56.1)                | 312 (54.6)                    | 121 (60.2) | 0.34   |
| Ischaemic                   | 230 (29.8)                | 169 (29.6)                    | 61 (30.3) | 0.84   |
| Hypertrophic                | 11 (1.4)                  | 9 (1.6)                       | 2 (1.0)  | 0.55   |
| Toxic                       | 34 (4.4)                  | 28 (4.9)                      | 6 (3.0)  | 0.17   |
| Idiopathic                  | 78 (10.1)                 | 56 (9.8)                      | 22 (10.9) | 0.65   |
| Multisite pacing            | 63 (8.2)                  | 45 (7.9)                      | 18 (9.0)  | 0.75   |
| Defibrillator               | 127 (16.5)                | 96 (16.8)                     | 31 (15.4) | 0.75   |
| Coronary artery bypass grafting | 62 (8.0)                 | 43 (7.5)                      | 19 (9.5)  | 0.58   |
| Percutaneous coronary intervention | 166 (21.5)              | 123 (21.5)                    | 43 (21.4) | 0.84   |
| Peripheral artery disease   | 91 (11.8)                 | 72 (12.6)                     | 19 (9.5)  | 0.41   |
| Stroke                      | 62 (8.0)                  | 42 (7.4)                      | 20 (10.0) | 0.43   |
| Chronic renal failure       | 164 (21.2)                | 104 (18.2)                    | 60 (29.9) | 0.002  |
| Dialysis                    | 11 (1.4)                  | 8 (1.4)                       | 3 (1.5)  | 0.84   |
| Chronic obstructive pulmonary disease | 50 (6.5)            | 33 (5.8)                      | 17 (8.5)  | 0.35   |
| Active cancer               | 51 (6.6)                  | 36 (6.3)                      | 15 (7.5)  | 0.72   |
| Previous medications, n (%) |                           |                               |         |
| Aspirin                     | 288 (37.3)                | 210 (36.8)                    | 78 (38.8) | 0.63   |
| P2Y12 inhibitors            | 126 (16.3)                | 96 (16.8)                     | 30 (14.9) | 0.57   |
| Statins                     | 286 (37.0)                | 210 (36.8)                    | 76 (37.8) | 0.69   |
| Beta blockers               | 316 (41.0)                | 232 (40.6)                    | 84 (41.8) | 0.68   |
| Vitamin K antagonist        | 165 (21.4)                | 108 (18.9)                    | 57 (28.4) | 0.01   |
| Direct oral anticoagulant   | 56 (7.3)                  | 48 (8.4)                      | 8 (4.0)  | 0.08   |
| ACE inhibitors or ARB       | 292 (37.8)                | 213 (37.3)                    | 79 (39.3) | 0.63   |
| Sacubitril/valsartan        | 18 (2.3)                  | 15 (2.6)                      | 3 (1.5)  | 0.40   |
| Loop diuretics              | 376 (48.7)                | 266 (46.6)                    | 110 (54.7) | 0.11  |
| Aldosterone antagonist      | 108 (14.0)                | 82 (14.4)                     | 26 (12.9) | 0.60   |
| Amiodarone                  | 132 (17.6)                | 98 (17.5)                     | 34 (17.7) | 0.95   |
| Proton pump inhibitor       | 276 (36.4)                | 206 (36.6)                    | 70 (35.7) | 0.83   |

ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; SD, standard deviation.
### Table 2  Clinical, echocardiographic and biological presentation according to vital status at 30 days

| Clinical presentation at admission                                      | Overall population (n = 772) | 30 day survivors (n = 571) | 30 day non-survivors (n = 201) | P value |
|-------------------------------------------------------------------------|-------------------------------|-----------------------------|--------------------------------|---------|
| Heart rate, mean ± SD, bpm                                              | 96 ± 30                       | 95 ± 30                     | 98 ± 27                        | 0.19    |
| SBP, mean ± SD, mmHg                                                    | 101 ± 25                      | 103 ± 25                    | 96 ± 26                         | <0.001  |
| DBP, mean ± SD, mmHg                                                    | 63 ± 17                       | 64 ± 17                     | 59 ± 17                         | <0.001  |
| Sinus rhythm, n (%)                                                     | 399 (52.0)                    | 308 (54.3)                  | 91 (45.3)                      | 0.03    |
| Cardiac arrest, n (%)                                                   | 79 (10.3)                     | 54 (9.5)                    | 25 (12.4)                      | 0.12    |
| Mottling, n (%)                                                         | 248 (37.5) N = 660            | 169 (37.1)                  | 79 (45.7)                      | 0.045   |
| Blood tests at admission, median (IQR)                                 |                               |                             |                                |         |
| Sodium, mmol/L                                                         | 135 (132–139) N = 760         | 136 (132–139) N = 559       | 135 (131–139) N = 201          | 0.15    |
| eGFR, ml/min/1.73 m²                                                    | 46 (28–67) N = 751            | 49 (32–70) N = 553          | 38 (23–54) N = 198             | <0.001  |
| Bilirubin, mg/L                                                        | 16 (9–29) N = 544             | 16 (9.5–28) N = 395         | 17 (9–31) N = 149              | 0.17    |
| Haemoglobin, g/dL                                                       | 12.6 (11.0–14.0) N = 754     | 13.0 (11.0–14.0) N = 555    | 12.0 (11.0–14.0) N = 199       | 0.02    |
| Arterial blood lactates, mmol/L                                        | 3.0 (2.0–4.75) N = 684       | 2.9 (2.0–4.2) N = 499       | 3 (2.0–5.0) N = 185            | <0.001  |
| ASAT, IU/L                                                             | 90.0 (39.0–301.0) N = 547    | 80.50 (37.0–286.3) N = 396  | 121.00 (46.0–468.0) N = 151    | 0.92    |
| ALAT, IU/L                                                             | 59.0 (27.0–183.0) N = 459    | 58.0 (26.0–182.0) N = 407   | 62.0 (31.0–199.8) N = 152      | 0.81    |
| NT proBNP, pg/mL                                                       | 9277 [4045; 23810] n = 224   | 7503 [3504; 16 845] n = 156 | 13 701 [5 386; 35 000] n = 68  | <0.001  |
| BNP, pg/mL                                                             | 1150 [476; 2778] n = 264     | 1082 [441; 2561] n = 205    | 1670 [762; 3484] n = 59        | 0.04    |
| CRP, mg/L                                                              | 28 (9–69) N = 406            | 26 (9–62) N = 300           | 40 (9–96.5) N = 106            | 0.001   |
| Baseline echocardiography                                               |                               |                             |                                |         |
| LVEF, mean ± SD, %                                                      | 26 ± 13                       | 27 ± 13.5                   | 24.5 ± 13                      | 0.004   |
| N = 763                                                                | N = 564                       | N = 199                     |                                |         |
| TAPSE, mm; median (IQR)                                                | 13 [10–16]                   | 13 [10–17]                  | 12 [9–16]                      | 0.6     |
| N = 772                                                                | N = 195                      | N = 60                      |                                |         |
| PSVtdi, cm/s; median (IQR)                                             | 8 [6–11]                     | 8 [6–11]                    | 9 [7–11]                       | 0.23    |
| N = 206                                                                | N = 155                     | N = 51                      |                                |         |
| Severe mitral regurgitation, n (%)                                      | 107 (14.6)                   | 79 (14.5)                   | 28 (14.5)                      | 0.96    |
| Severe aortic stenosis, n (%)                                          | 36 (4.7)                     | 22 (3.9)                    | 14 (7.1)                       | 0.03    |
| Severe aortic regurgitation, n (%)                                      | 10 (1.3)                     | 6 (1.1)                     | 4 (2.1)                        | 0.28    |

ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARB, angiotensin-receptor blocker; ASAT, aspartate aminotransferase; CRP, C-reactive protein; DBP, diastolic blood pressure; PSVtdi, peak systolic velocity tissue Doppler imaging; SBP, systolic blood pressure; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion.
ICCU, 31.5% for ICU, and 36.4% for patients transferred from another centre (emergency or another department); \( P = 0.04 \). Mortality at 30 days was numerically higher but non-significant with a higher number of CS triggers (21.4%: absent, 27.3%: one, 27.5%: two, and 37.5%: three or more).

**Baseline characteristics and 30 day mortality**

Clinical characteristics according to vital status at 30 days are presented in Table 1. Overall, non-survivors at 30 days were older (70.4 ± 14.3 years vs. 64.0 ± 14.8 years) with similar gender ratios. No significant difference was observed in risk factors and comorbidities except for CKD (30 day survivors: 18.2%; 30 day non-survivors: 29.9%).

Cardiogenic shock mortality also depended on the trigger (Figure 1). In the overall population, ischaemia was the most frequent CS trigger while infectious disease was more frequent in non-survivors (18.9% vs. 9.5%). The proportion of cardiac arrests was numerically higher in non-survivors. In resuscitated cardiac arrest patients, mortality was 31.6% (and 48.8% in non-ischaemic cardiac arrest).

At admission, non-survivors had a lower SBP and diastolic blood pressure, a higher heart rate and less sinus rhythm (Table 2). They had a lower LVEF (24.5% ± 13 vs. 27% ± 13.5) and more severe aortic stenosis (7.1% vs. 3.9%). They had higher arterial blood lactate and inflammatory markers (C-reactive protein), more severe kidney failure and lower haemoglobin.

**Outcomes in relation to early management**

In-hospital management according to vital status at 30 days is presented in Table 3. The rate of intravenous diuretics was numerically higher in survivors group (83.9 vs. 76.6%). Dobutamine was prescribed for 85.6% of the non-survivors compared with 80.6% of the survivors, for whom numerically, higher doses (>15 µg/kg/min) were fewer. Epinephrine and norepinephrine were used more often in non-survivors. Invasive respiratory support was more frequent in non-survivors (46.2% vs. 35%) as were renal replacement therapy and circulatory support.

Coronary angiography was performed in 55.7% of survivors and 40.3% of non-survivors (\( P < 0.001 \)). However, the number of diseased vessels and the rate of PCI were similar in both groups.

Most in-hospital complications were similar in survivors and non-survivors, except for stroke (non-survivors: 9%; vs. survivors: 3.2%) (Table S4). Pneumonia was the most common infectious complication in both groups (19.7%).

**Independent correlates of 30 day mortality**

Factors related to 30 day mortality are reported in Tables 4 and 5. At admission, age (per year: OR 1.03, 95% CI: 1.02–1.05), infectious trigger (OR 2.10, 95% CI: 1.26–3.50), and LVEF <30% (OR 1.79, 95% CI: 1.21–2.64) were independently associated with higher mortality at 30 days. High lact-
tate levels (>4 mmol/l) were also associated with higher mortality (OR 2.07, 95% CI: 1.19–3.58).

With full adjustment (Model 2), independent factors associated with mortality at 30 days were (Table 5): age (per year [OR 1.06, 95% CI: 1.04–1.08]), LVEF <30% (OR 2.15, 95% CI: 1.40–3.29), circulatory support (OR 1.92, 95% CI: 1.12–3.29), renal replacement therapy (OR 2.72, 95% CI 1.65–4.49), and the use of norepinephrine (OR 2.55, 95% CI: 1.69–3.84) and of diuretics (OR 1.74, 95% CI: 1.05–2.88). In addition, invasive (OR 1.14, 95% CI: 0.68–1.90) and non-invasive respiratory support (OR 0.83, 95% CI: 0.51–1.34), PCI (OR 0.64, 95% CI: 0.41–1.01) and dobutamine (OR 1.27, 95% CI: 0.74–2.19) were not associated with 30-day-mortality in our analysis.

Similarly, in patients with ischaemic CS, the use of PCI was not associated with a significantly lower mortality (OR 0.63, 95% CI: 0.32–1.25).

Table S5 describes all ORs and 95% CIs of all variables tested in Models 1 and 2.

### Discussion

To date, the FRENSHOCK registry is the largest European prospective, observational multicentre study on CS that describes a contemporary cohort of unselected patients with CS, from a broad spectrum of aetiologies. The main findings and the originality of this study are the diversity of patient profiles and CS aetiologies linked to the inclusion of patients in different departments (ICU, ICCU, etc.). Although ischaemia remains the primary trigger, it represented only 36.3% of the causes of CS. Secondary, mortality rate at 30 days was 26.0% in the overall population but varied according to the trigger and the first place of admission (ICU, ICCU, transfer from another hospital), and ranged from 16.7% to 48.0%. Finally, six independent factors (age, LVEF <30%, circulatory support, renal replacement therapy, the use of norepinephrine and diuretics) were associated with higher mortality at 30 days.
An inadequate definition of cardiogenic shock in current practice

Numerous definitions of CS have been suggested, but it is broadly recognized as a state of low cardiac output resulting in end-organ hypoperfusion. The definition of CS has evolved over the years from persistent hypotension (starting with SBP < 80 mmHg, followed by SBP < 90 mmHg or use of pressors to maintain a SBP > 90 mmHg) to several hemodynamic parameters described in the SHOCK trial. These hemodynamic parameters may not be universally applicable in clinical practice. In our registry, the first mean SBP was high for a CS population (101 ± 25 mmHg) with a high rate of patients with SBP ≥ 90 mmHg (507/772). Of these, 463 patients

Table 4  Characteristics that affect 30 day mortality for all patients with cardiogenic shock (adjusted for clinical characteristics)

| Characteristic               | OR (95% CI) | P value |
|------------------------------|-------------|---------|
| Age (per year)               | 1.03 (1.02–1.05) | <0.001 |
| Infectious trigger           | 2.10 (1.26–3.50) | 0.005   |
| LVEF <30%                    | 1.79 (1.21–2.64) | 0.004   |
| Lactate level                |             |         |
| <2 mmol/L                    | Ref         |         |
| ≥2 and <4 mmol/L            | 1.61 (0.92–2.83) | 0.09    |
| ≥4 mmol/L                    | 2.07 (1.19–3.58) | 0.01    |

CI, confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio.

Table 5  Independent variables associated with 30 day mortality in all patients with cardiogenic shock (adjusted for clinical characteristics and management)

| Characteristic               | OR (95% CI) | P value |
|------------------------------|-------------|---------|
| Age (per year)               | 1.06 (1.04–1.08) | <0.001 |
| LVEF <30%                    | 2.15 (1.40–3.39) | <0.001 |
| Mechanical circulatory support | 1.92 (1.12–3.29) | 0.02    |
| Renal replacement therapy    | 2.72 (1.65–4.49) | <0.001 |
| Use of norepinephrine        | 2.55 (1.69–3.84) | <0.001 |
| Use of diuretics             | 1.74 (1.05–2.88) | 0.03    |

CI, confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio.

An inadequate definition of cardiogenic shock in current practice

Numerous definitions of CS have been suggested, but it is broadly recognized as a state of low cardiac output resulting in end-organ hypoperfusion. The definition of CS has evolved over the years from persistent hypotension (starting with SBP < 80 mmHg, followed by SBP < 90 mmHg or use of pressors to maintain a SBP > 90 mmHg) to several hemodynamic parameters described in the SHOCK trial. These hemodynamic parameters may not be universally applicable in clinical practice. In our registry, the first mean SBP was high for a CS population (101 ± 25 mmHg) with a high rate of patients with SBP ≥ 90 mmHg (507/772). Of these, 463 patients

ESC Heart Failure 2022; 9: 408–419
DOI: 10.1002/ehf2.13734
(91.3%) had vasopressor or circulatory support. This indicates that patients were included at different times after CS.

The common definition of CS is binary (CS present or absent), while in fact CS should be considered as a continuum from mild haemodynamic perturbations observed in pre-shock or mild shock, progressing to shock, profound shock, and finally refractory shock which invariably results in death.16 A new five-stage CS classification was recently proposed by the Society for Cardiovascular Angiography and Interventions (SCAI) (A: ‘At risk’; B: ‘Beginning’; C: ‘Classic’; D: ‘Deteriorating’; E: ‘Extremis’) to depict the entire spectrum of CS and predict the risk of death in ICCUs.12,17 It may be difficult to use a posteriori in our registry and would therefore require adaptation as in the recent Cardiogenic Shock Working Group publication.18 Our pragmatic and practical definition of CS is based on simple criteria available at the patient’s bedside in any centre, regardless of the level of expertise, allowing rapid recognition of CS from among the different CS aetiologies and presentations without excluding non-ischaemic aetiologies or unusual presentations (low cardiac output without severe hypotension, right ventricular failure) which may concern almost 40 to 50% of CS cases.

Clinical characteristics compared with previous European observational studies

Clinical characteristics of the FRENSHOCK population show similarities with previous large European multinational observational studies (219 patients in 6 centres in the CardShock study, and 195 patients in 211 centres in 21 countries in the ESC Heart Failure Long-Term Registry).19,20 Table S6 compares main characteristics of these studies. Mean age (66 vs. 67 years), percentage of men (72% vs. 60 to 74%), risk factors, and medical history are similar. As in the CardShock study, our patients were included from emergency departments, ICCU, and ICU; although in other studies inclusions were only in cardiology departments.11,12,20 But inclusion criteria were different and more restrictive in CardShock with exclusion of CS caused by ongoing haemodynamically significant arrhythmias, although these are frequent in our registry (13.3% supra ventricular arrhythmias and 12.6% ventricular arrhythmias as CS triggers), and easily reversible causes potentially associated with a better prognosis. Moreover, in CardShock, patients were enrolled within 6 h of detection of CS, which explains the difference regarding biological and clinical presentation, especially haemodynamic parameters (e.g. SBP).

Cardiogenic shock triggers

Cardiogenic shock was long forgotten by cardiology research before being restricted to the form secondary to MI.6–7 This can be explained by the fact that the underlying pathology and management differ from non-ischaemic cases. The rate of ischaemic CS (36% in our study) is variable according to the study, but classically stays the main aetiology (57.9 to 80.8%)19,20 even if other studies have indicated more heterogeneous and non-ischaemic aetiologies (42.3 to 56.9%).11–13 Non-ischaemic CS can be caused by a variety of diseases or triggers which lead to severe myocardial dysfunction (either through acute decompensation in chronic heart failure or de novo).12,20 In our population, ventricular and supra-ventricular arrhythmias and infectious triggers were frequent and concerned respectively 12.6%, 13.3%, and 11.9% of our CS cases (CS precipitants in respectively 18.9%, 26.2%, and 24.6% in the ESC Heart Failure registry).20 Unfortunately, the causes of non-ischaemic CS are rarely specified in the available studies and registers, and direct comparison is therefore impossible.11–13

Mortality and predictors of hospital death

The mortality rate observed in the FRENSHOCK registry (26%; range 16.7% to 48% according to the cause of CS) is lower than in previous studies where hospital mortality was between 30% and 40%.13,18,19–21 The comparatively low short-term mortality observed in FRENSHOCK can be explained by several factors. First, it could be secondary to the FRENSHOCK definition used, but our 30 day mortality was quite similar regardless of the usual CS definitions used (respectively 26.8% and 28.3% for patients meeting the ESC-Heart failure and IABP-Shock2 definitions). Second, our inclusions were in 2016 and more recent than previous retrospective analyses which included patients for longer periods between 2005 and 2017.11,12,20 Third, our lower mortality is related to differences in presentation, especially less severe baseline biological and haemodynamic parameters. This was in part related to the timing of inclusion relative to the time of shock onset, and to the variety of recruiting units (ICCU and ICU), as illustrated by the lower mortality in ICU. In addition, our registry does not make it possible to differentiate isolated CS from mixed shocks, which may explain part of the observed differences in mortality compared with previous studies. The wider use of RHC could have helped to better classify these patients, but remains little carried out in France to date, even if recent US data found a possible link between its use and the short-term prognosis of CS patients.22 Another factor might be that the in-hospital mortality rate for patients with non-acute coronary syndrome CS decreased between 2005 and 2014 from 42.4% to 23.3% as suggested in a large database (8 333 752 hospitalizations for heart failure) in the United States (P value for trend <0.001).14

Data related to the prognosis of CS according to ischaemic or non-ischaemic trigger have shown conflicting results.10,13,14,21 However, ischaemic CS is mainly associated
with lower in-hospital mortality except in the CardShock study. An improvement in survival has been observed over the past two decades, attributed to the introduction of routine percutaneous revascularization in AMI and modern intensive care. But in our analyses, ischaemic cause was not associated with improved mortality and the impact of PCI on survival at 30 days was not significant as in the CardShock study.

In the multivariate analysis, four independent factors at admission (age, LVEF <30%, lactate ≥4 mmol/L, infectious trigger) were associated with higher mortality at 30 days. In the CardShock study, the predictors of in-hospital death were different and included: prior coronary artery bypass surgery, ACS aetiology, confusion, previous MI, blood lactate, LVEF, age and SBP. Other previously published studies have identified diverse factors associated with short-term mortality but these were related to CS aetiologies (mainly or only based on ischaemic CS) and the patient inclusion settings (mainly or exclusively in general ICUs). Thus, faced with very similar initial characteristics on admission, it is difficult to predict on simple static elements, the prognosis of patients presenting for miscellaneous CS. In this sense, the use of the recent SCAI classification taking into account the evolution under treatment seems advantageous. Finally, the level of invasiveness of the treatment reflects the severity of the patient’s presentation and the advanced shock state (norepinephrine, renal replacement therapy, and mechanical circulatory support) and is correlated with short-term prognosis without any significant difference depending on the type of support used (IABP, Impella or VA-ECMO for example).

Limitations

As in any observational study, there are limitations to our analysis. First, inclusions were not exhaustive and probably not consecutive in all centres. Moreover, non-inclusions and the reasons for non-inclusion were not presented. Second, patients were enrolled from ICU and ICCU (directly or after transfer from another centre) and we cannot exclude the possibility that severe comorbid, older, or most severe cases with multiple organ failure could have not been transferred for futility even if the older patient included was 98 years old. Moreover, data for patients who died early (before informed consent was obtained) were not collected and recorded in the database because of administrative regulations. This could be a source of bias resulting in an underestimation of mortality. Third, certain aetiologies or triggers of CS were not recorded in the electronic reported form and were therefore not collected (takotsubo, pulmonary embolism, acute decompensation of chronic heart failure, aetiologies of infectious triggers, etc.). Subsequently, a conclusion could not be drawn regarding them. In addition, causality between CS and 30 day mortality cannot be demonstrated. However, we adjusted our results based on well-recognized determinants of short-term outcome and sensitivity analyses confirmed our main findings. The period between admission and CS onset and from CS onset to enrolment in the registry were not recorded which may explain why some parameters described were not as high as expected (e.g. lactate levels could have been high at CS onset and not at inclusion). Finally, other previously identified risk indicators (e.g. confusion, medications, timing of revascularization, and organ support) were not recorded in our database.

Conclusions

Cardiogenic shock is characterized by its diversity in terms of aetiologies and severity. Ischaemic CS remains the main CS trigger but non-ischaemic causes accounted for more than 60% of all the cases. CS is still associated with significant but variable short-term mortality according to the cause and first place of admission, despite more frequent use of haemodynamic support and organ replacement therapies.

Acknowledgements

FRENSHOCK is a registry of the French Society of Cardiology, managed by its Emergency and Acute Cardiovascular Care Working Group. Our thanks go out to all the devoted personnel of Société Française de Cardiologie who actively participate in the upkeep of the registry especially N. Naccache, E. Drouet, and V. Bataille. The authors are deeply indebted to all the physicians who took care of the patients at the participating institutions.

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

The study was sponsored by the Fédération Française de Cardiologie and was funded by unrestricted grants from Daiichi-Sankyo and Maquet SAS. Complementary grants will be sought for dedicated research projects within the main study.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.
Table S1. FRENSHOCK definition of cardiogenic shock.

Table S2. Criteria used to define cardiogenic shock in the FRENSHOCK population.

Table S3. Vital parameters at 24 hours according to vital status at 30 days.

Table S4. In-hospital complications according to vital status at 30 days.

Table S5. Description of all odds ratios and 95% confidence intervals of all variables tested in multivariate analysis models in-hospital all-cause mortality: model 1 (based only variables available on admission) and model 2 (based on variables available at admission and on variables of in-hospital management).

Table S6. Comparison of major population characteristics and outcomes between the FRENSHOCK, the CardShock and the ESC Heart Failure Long-Term registries.

References

1. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, Harjola VP, Antohi EL, Arigo M, Gal TB, Celutkiene J, Collins SP, DeBacker D, Iliescu VA, Jankowska E, Jaarsma T, Keramida K, Lainscak M, Lund LH, Lyon AR, Masip J, Metra M, Miro O, Mortara A, Mueller C, Mullens W, Nikolou M, Piepoli M, Price S, Rosano G, Veillard-Baron A, Weinstein JM, Anker SD, Filippatos G, Ruschitzka F, Coats AJS, Seferovic P. Epidemiology, pathophysiology and contemporary management of cardiogenic shock—a position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2020; 22: 1315–1341.

2. Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, Col J, LeJemtel T. Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. *Am Heart J* 1999; 137: 313–321.

3. Van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Monos M, Menon V, Ohman EM, Switzer NK, Thiele H, Washam JB, Cohen MG. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. *Circulation* 2017; 136: e232–e268.

4. Bahaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA* 2005; 294: 448–454.

5. Jeger RV, Radovanovic D, Huzniker PR, Pisterer ME, Stauffer JC, Erne P, Urban P. AMIS plus registry investigators. Ten-year trends in the incidence and treatment of cardiogenic shock. *Ann Intern Med* 2008; 149: 618–626.

6. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. *Circulation* 2009; 119: 1211–1219.

7. Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefèvre T, Durand E, Blanchard D, Simon T, Cambou JP, Danchin N. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. *Eur Heart J* 2012; 33: 2535–2543.

8. Goldberg RJ, Makam RC, Yarzebski J, McManus DD, Lessard D, Gore JM. Decade-long trends (2001–2011) in the incidence and hospital death rates associated with the in-hospital development of cardiogenic shock after acute myocardial infarction. *Circ Cardiovasc Qual Outcomes* 2016; 9: 117–125.

9. Davierwala PM, Leontyev S, Verevkin A, Rastan AJ, Mohr M, Bakhhtary F, Misfeld M, Mohr FW. Temporal trends in predictors of early and late mortality after emergency coronary artery bypass grafting for cardiogenic shock complicating acute myocardial infarction. *Circulation* 2016; 134: 1224–1237.

10. Schrage B, Weimann J, Dabboura S, Yan I, Hilal R, Reberc PM, Seiffert M, Bernhardt AM, Kluge S, Reichenspurner H, Blankenberg S, Westermann D. Patient characteristics, treatment and outcome in non-ischemic vs. ischemic cardiogenic shock. *J Clin Med* 2020; 9: 931.

11. Schrage B, Dabboura S, Yan I, Hilal R, Neumann JT, Sörensen NA, Gößling A, Reberc PM, Grahn H, Wagner T, Seiffert M, Kluge S, Reichenspurner H, Blankenberg S, Westermann D. Application of the SCAI classification in a cohort of patients with cardiogenic shock. *Catheter Cardiovasc Interv* 2020; 96: E213–E219.

12. Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, Naidu SS, Baran DA. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. *J Am Coll Cardiol* 2019; 74: 2117–2128.

13. Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis AP, Haleem A, Hollenberg SM, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Park JG, Phreuner N, Roswell RO, Schulman SP, Jeffrey Snell R, Solomon MA, Ternus B, Tymchak W, Vikram F, Morrow DA. Epidemiology of shock in contemporary cardiac intensive care units. *Circ Cardiovasc Qual Outcomes* 2019; 12: e005618.

14. Yandrapalli S, Sanaani A, Harikrishnan P, Aronow WS, Frishman WH, Lanier GM, Ahmed A, Fonarow GC. Cardiogenic shock during heart failure hospitalizations: age-, sex-, and race-stratified trends in incidence and outcomes. *Am J Cardiol* 2019; 213: 18–29.

15. Delmas C, Puymirat E, Leurent G, Elbazz M, Manzo-Silberman S, Bonello L, Gerbad E, Bataille V, Levy B, Lamblin N, Bonnefoy E, Henry P, Roubille F, FRENSHOCK investigators. Design and preliminary results of FRENSHOCK 2016: a prospective nationwide multicentre registry on cardiogenic shock. *Arch Cardiovasc Dis* 2019; e112: 343–353.

16. Bellumkonda L, Gul B, Masić SR. Evolving concepts in diagnosis and management of cardiogenic shock. *Am J Cardiol* 2018; 122: 1104–1110.

17. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, Hollenberg SM, Kapur NK, O’Neill W, Ornato JP, Stelling K, Thiele H, van Diepen S, Naidu SS. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 2019; 94: 29–37.

18. Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, Morine KJ, Newman S, Jorde L, Haywood JL, Harwani NM, Esposito ML, Davila CD, Wenczer D, Sinha SS, Vorovich E, Abraham J, O’Neill W, Udelson J, Burkhoff D, Kapur NK. Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock. *Circ Heart Fail* 2020; 13: e007099.
19. Harjola VP, Lassus J, Sionis A, Kober L, Tarvamasäki T, Spinar J, Parissis J, Banaszewski M, Silva-Cardoso J, Carubelli V, Di Somma S, Tolppanen H, Zeymer U, Thiele H, Nieminen MS, Mebazaa A. CardShock study investigators; GREAT network. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. *Eur J Heart Fail* 2015; 17: 501–509.

20. Chioncel O, Mebazaa A, Harjola VP CAJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017; 19: 1242–1254.

21. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K, IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 2012; 367: 1287–1296.

22. Garan AR, Kanwar M, Thayer KL, Whitehead E, Zweck E, Hernandez-Montfort J, Mahr C, Haywood JL, Harwani NM, Wencker D, Sinha SS, Vorovich E, Abraham J, O’Neill W, Burkhoff D, Kapur NK. Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. *JACC Heart Fail* 2020; 8: 903–913.

23. Krishnan U, Brejt JA, Schulman-Marcus J, Swaminathan RV, Feldman DN, Chiu Wong S, Goyal P, Horn EM, Karas M, Sobol I, Minutello RM, Bergman G, Singh H, Kim LK. Characteristics of hospitalizations for cardiogenic shock after acute myocardial infarction in the United States. *Int J Cardiol* 2017; 244: 213–219.

24. Pöss J, Köster J, Fuernau G, Eitel I, de Waha S, Ouarrak T, Lassus J, Harjola VP, Zeymer U, Thiele H, Desch S. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol* 2017; 69: 1913–1920.